Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks

Minerva Neurosciences, Inc.

Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.
Phase 3 C19 trial relapse assessment phase extended from 40 to 52 weeks after FDA feedback.
Topline efficacy results from C19 trial expected H2 2027; relapse data expected H2 2028.
No obligation to sell any shares; program provides capital-raising flexibility.

item 1.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-241930
form_type: 8-K
ticker: NERV
cik: 0001598646
company_name: Minerva Neurosciences, Inc.
filed_at: 2026-05-27T20:18:04+00:00
discovered_at: 2026-05-27T20:19:00.167420+00:00
generated_at: 2026-05-27T20:20:13.127688+00:00
sec_items: ["1.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-241930
json_url: https://secwatch.observer/filing/0001193125-26-241930.json
markdown_url: https://secwatch.observer/filing/0001193125-26-241930.md
text_url: https://secwatch.observer/filing/0001193125-26-241930.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/0001193125-26-241930-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/d119518d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CLIR

ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds

ClearSign Technologies Corp June 1, 2026, 8:30 AM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

RDAC

Shareholders approve SPAC extension to Oct 15, 2027; ~1.9M shares redeemed

Rising Dragon Acquisition Corp. June 1, 2026, 6:08 AM ET other_material Items 1.01, 5.03, 5.07, 8.01, 9.01

same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EMYB

Embassy Bancorp expands stock repurchase program by additional $5M

Embassy Bancorp, Inc. June 1, 2026, 4:37 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTXR

Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

Citius Pharmaceuticals, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-241930

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.